Thornburg Investment Management Inc. Purchases 28,124 Shares of Vera Therapeutics, Inc. (NASDAQ:VERA)

Thornburg Investment Management Inc. boosted its stake in Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) by 91.1% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 59,004 shares of the company's stock after purchasing an additional 28,124 shares during the period. Thornburg Investment Management Inc. owned about 0.09% of Vera Therapeutics worth $2,495,000 at the end of the most recent reporting period.

A number of other large investors have also bought and sold shares of VERA. Avoro Capital Advisors LLC increased its stake in shares of Vera Therapeutics by 30.2% during the fourth quarter. Avoro Capital Advisors LLC now owns 5,610,000 shares of the company's stock valued at $237,247,000 after buying an additional 1,300,410 shares during the period. Price T Rowe Associates Inc. MD increased its stake in shares of Vera Therapeutics by 11.1% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 4,377,049 shares of the company's stock valued at $185,107,000 after buying an additional 437,940 shares during the period. FMR LLC increased its stake in shares of Vera Therapeutics by 9.6% during the fourth quarter. FMR LLC now owns 3,053,126 shares of the company's stock valued at $129,117,000 after buying an additional 267,842 shares during the period. Vanguard Group Inc. boosted its position in shares of Vera Therapeutics by 14.3% during the fourth quarter. Vanguard Group Inc. now owns 2,949,564 shares of the company's stock valued at $124,737,000 after purchasing an additional 369,387 shares in the last quarter. Finally, Paradigm Biocapital Advisors LP grew its stake in Vera Therapeutics by 31.0% in the fourth quarter. Paradigm Biocapital Advisors LP now owns 1,437,339 shares of the company's stock worth $60,785,000 after purchasing an additional 340,488 shares during the period. 99.21% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

VERA has been the topic of several recent research reports. Cantor Fitzgerald reduced their price target on Vera Therapeutics from $107.00 to $100.00 and set an "overweight" rating on the stock in a research note on Wednesday, May 7th. HC Wainwright initiated coverage on Vera Therapeutics in a research note on Monday, May 5th. They issued a "buy" rating and a $75.00 price target on the stock. Wedbush reduced their price target on Vera Therapeutics from $34.00 to $26.00 and set a "neutral" rating on the stock in a research note on Wednesday, May 7th. The Goldman Sachs Group initiated coverage on Vera Therapeutics in a research note on Tuesday, January 28th. They issued a "buy" rating and a $58.00 price target on the stock. Finally, Guggenheim upped their price target on Vera Therapeutics from $59.00 to $61.00 and gave the stock a "buy" rating in a research note on Thursday, February 27th. One equities research analyst has rated the stock with a hold rating, seven have issued a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, Vera Therapeutics has a consensus rating of "Buy" and an average target price of $63.33.

Vera Therapeutics Stock Down 4.0%

Vera Therapeutics stock traded down $0.85 during mid-day trading on Wednesday, hitting $20.39. The company had a trading volume of 634,906 shares, compared to its average volume of 782,169. The company has a current ratio of 13.76, a quick ratio of 13.76 and a debt-to-equity ratio of 0.17. The stock's 50 day moving average price is $23.07 and its two-hundred day moving average price is $33.58. Vera Therapeutics, Inc. has a 12 month low of $18.53 and a 12 month high of $51.61. The company has a market capitalization of $1.30 billion, a PE ratio of -7.81 and a beta of 1.28.

Vera Therapeutics (NASDAQ:VERA - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The company reported ($0.81) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.75) by ($0.06). During the same quarter in the previous year, the company earned ($0.56) earnings per share. As a group, sell-side analysts anticipate that Vera Therapeutics, Inc. will post -2.89 earnings per share for the current fiscal year.

Vera Therapeutics Company Profile

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.